STOP-HS1 And STOP-HS2 Trials Evaluating Safety And Efficacy Of Povofortay In Patients With Moderate To Severe HS Met The Primary Endpoint
Benzinga Newsdesk 1 hour ago
BiotechGeneralNews
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
The overall safety profile of Povofortay over 54 weeks was consistent with previously reported data; both doses were well tolerated, with no new or unexpected safety signals. The most frequent TEAEs across both studies and doses were acne, nasopharyngitis and upper respiratory tract infections with most events reported as mild or moderate.2
